Purpose: To evaluate early versus late immunomodulatory therapy (IMT) for patients following initial diagnosis of Vogt-Koyanagi-Harada (VKH) disease.
Introduction
Vogt-Koyanagi-Harad disease (VKH) is a bilateral panuveitis that primarily affects pigmented ethnicities including Hispanic, Asian, and Native Americans. 1 Also known as uveomeningitis syndrome, VKH is an idiopathic inflammatory disease characterized by chronic, diffuse, granulomatous panuveitis frequently associated with neurological, auditory, and integumentary manifestations. 2 While the exact cause of the disease remains unknown, T-lymphocyte-mediate autoimmunity against tyrosinase peptides of melanocytes is present. 3, 4 A genetic predisposition has been shown with an association between VKH and HLA-DR1 and HLA-DR4 in
Hispanics as well as several HLA specificities in Asians. [5] [6] [7] While the disease is more prevalent in Asia, VKH accounts for between 1% to 4% of uveitis referrals within the United States. 8, 9 Vogt-Koyanagi-Harada disease generally presents in four phases: 1) a prodromal phase with auditory and neurologic symptoms 2) an acute uveitic phase, which may include diffuse choroiditis, exudative retinal detachment, and intraocular inflammation 3) a chronic phase, consisting of variable depigmentation of the fundus and limbus in addition to vitiligo, poliosis, and alopecia and 4) a chronic-recurrent phase with iridocyclitis, which may be chronic, recurrent or both. 10 The majority of people treated for VKH are prescribed Immunomodulatory agents used included mycophenolate mofetil, cyclosporine, azathioprine, methotrexate, infliximab, and adalimumab.
Clinical outcomes are summarized in Table 2 . 0.11) compared to the late IMT group although these differences did not reach statistical significance.
In terms of common complications, previous studies of VKH have reported glaucoma or ocular hypertension to occur in 6-45% of eyes and cataracts to develop in 11-42% of eyes. 1, 16, 17 In our study, ocular hypertension was the most common complication occurring in 46.5% of patients, which is at the high range of previous estimates. Previous evaluations of patients with VKH have shown that the development of complications is directly associated with increased follow-up time. 16 We hypothesize that our relatively high rate of ocular hypertension may be due to the long average follow-up of our patients (39.2 months) and that we defined ocular hypertension as uncontrolled IOP requiring intervention at any visit over the entire clinical course. Visually significant cataract occurred in just over one third of our patients, similar to prior studies. Subretinal fibrosis developed in approximately 10% of our patients similar to other reports ranging from 2.5-12% of cases. 1 Choroidal neovascularization was uncommon in our study occurring in only one eye. We found no differences in any ocular complications between the early and late IMT groups.
Corticosteroid taper in VKH is generally quite slow in order to avoid disease recurrences. Even with a prolonged taper, patients frequently have acute recurrences requiring a subsequent increase in corticosteroid therapy. We found that early IMT might allow for faster taper of corticosteroids without an increase in disease recurrence or inferior outcomes. Of the patients who were able to achieve a corticosteroid taper below 10mg oral prednisone daily, the early IMT 
